A carregar cotações...
Previsão
Não temos dados de analistas para esta empresa.
Discussões na comunidade
Ainda não há nenhuma discussão sobre este ativo.
Iniciar discussãoNotícias Ir para o feed de notícias
BioVersys: positive phase‑2 signals for antibiotic candidate BV100 in ventilator‑associated pneumonia
BioVersys will present data at IDWeek 2026 from a phase‑2 study of 26 patients in which BV100 combined with polymyxin B was tested against the best available standard therapy for ventilator‑associated pneumonia caused by multidrug‑resistant Acinetobacter baumannii. BV100 is an intravenously administered form of rifabutin and is being studied in two clinical trials; the drug is not yet approved. The data presentations will take place on 23 and 24 October 2026 in Washington. » Mais em finanzen.net
BioVersys share: investment from one year ago now down 13.33%
An investment of 1,000 CHF in BioVersys one year ago would be worth 866.67 CHF today, based on a price drop from 33.00 CHF to 28.60 CHF (minus 13.33%). That corresponds to holding 30.303 shares. Market capitalization most recently stood at around 167.67 million CHF. The first recorded price after the IPO was on 07.02.2025 at 36.50 CHF. » Mais em finanzen.net
BioVersys receives FDA fast-track for antibiotic BV100
The US FDA has granted BioVersys fast-track status for the intravenous antibiotic BV100, being developed to treat severe hospital-acquired pneumonia caused by the multidrug-resistant pathogen Acinetobacter baumannii. The designation enables more frequent contact with regulators and an expedited review phase for marketing submissions. BV100 exploits a previously unused uptake route in the bacterium and is currently in a global phase 3 trial as well as an open-label phase 2b study; an earlier phase 2 trial showed a 50% reduction in mortality versus the best available therapy. Approval has not yet been granted. » Mais em finanzen.net
BioVersys investment: 100 CHF a year ago would have yielded a 1.22% gain
A 100 CHF investment in BioVersys a year ago would have increased in value by 1.22% today; the closing price on 21.08.2026 was 24.80 CHF (previously 24.50 CHF). Market capitalization most recently stood at 145.46 million CHF. At the IPO on 07.02.2025 the initial price was set at 36.50 CHF. » Mais em finanzen.net
BioVersys: one-year loss of around 19.7% on a CHF 10,000 investment
A CHF 10,000 investment in BioVersys one year ago would have been worth only CHF 8,029.41 as of 24 July 2026, representing a decline of 19.71%. A share last cost CHF 27.30 and the market capitalization was CHF 159.66 million. Calculation does not take into account stock splits or dividends. » Mais em finanzen.net
